Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx® for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy.

Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx® for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy. Ann Surg Oncol. 2019 Oct; 26(10):3232-3239.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Breast Neoplasms
Carcinoma, Ductal, Breast
Carcinoma, Lobular
Chemotherapy, Adjuvant
Female
Follow-Up Studies
Gene Expression Profiling
Humans
Medical Overuse
Middle Aged
Neoadjuvant Therapy
Prognosis
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Retrospective Studies

authors with profiles

Katharine Yao